Why the study?
Diabetic cardiomyopathy is often associated with increased BNP levels, but the role of BNP in its development and the underlying mechanisms remained to be explored.
Does BNP protect against diabetic cardiomyopathy in preclinical models?
Population
Streptozotocin-induced diabetic mice and high-glucose-treated primary neonatal cardiomyocytes
Comparison
Exogenous BNP, BNP knockdown, Opa1 knockdown, NPRA knockdown, or PKG knockdown vs controls
Design
In vivo animal and in vitro experimental mechanistic study
Authors
Loading...
Suggests compensatory BNP protection in diabetic cardiomyopathy models; hypothesis-generating and requires human trials before clinical consideration.
Does BNP protect against diabetic cardiomyopathy in preclinical models?
BNP provides compensatory protection against diabetic cardiomyopathy by promoting mitochondrial fusion via the NPRA-PKG-STAT3-Opa1 signaling pathway.
Chang et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: